-
-
Overview
-
HIV associated PCR kits
Real-Time amplification test for the detection of HLA-B (major histocompatibility complex, class I, B) Allele 5701Please contact us at for specific academic pricing.
Background
Abacavir is a nucleoside reverse-transcriptase inhibitor with activity against the human immunodeficiency virus (HIV), available for once-daily use in combination with other antiretroviral agents, that has shown efficacy, few drug interactions, and a favorable long-term toxicity profile. The most important adverse effect of abacavir that limits its use in therapy and mandates a high degree of clinical vigilance is an immunologically mediated hypersensitivity reaction affecting 5 to 8% of patients during the first 6 weeks of treatment. In 2002, an association between a diagnosis of hypersensitivity reaction to abacavir and carriage of the major histocompatibility complex class I allelee HLA-B*5701 was reported independently by several independent studies.
Studies of cohorts with HIV infection have also shown that avoiding abacavir in HLA-B*5701 positive patients significantly reduced the incidence of suspected hypersensitivity reaction up to 0,5%. Many clinical studies recommend for this reason, the pharmacogenetic molecular testing of the carriage of the major histocompatibility complex class I allelee HLA-B*5701 in all HIV positive patients treated with abacovir.
HLA-B*5701 Real-TM test can predict who will develop a severe allergic reaction to the anti-HIV drug abacavir as the presence of HLA-B*5701 is significantly associated with an abacavir hypersensitivity.
-
- Properties
- Applications
-
Overview